Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06136195
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Alcohol Consumption
  • Alcohol Use Disorder (AUD)
  • Heavy Drinker

Eligibility Criteria

Sex
ALL
Age
21 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Mavoglurant — DRUG
    The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.

Study Details

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.

Key Dates

Start date
Jul 1, 2024
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
63 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Mavoglurant 1st / Placebo 2nd
    Participants randomized to the Mavoglurant 1st Arm will take a single dose of 200mg mavoglurant in the morning, prior to their 1st lab session. Then after a 5-8 day washout period, participants will have their 2nd lab session where they will take a matching placebo in the morning prior to the 2nd lab session.
  • Experimental: Placebo 1st / Mavoglurant 2nd
    Participants randomized to the Placebo 1st Arm will take a matching placebo in the morning, prior to their 1st lab session. Then after a 5-8 day washout period, participants will have their 2nd lab session where they will take a single dose of 200mg mavoglurant in the morning, prior to their 2nd lab session.

Primary Outcome Measure

Change in the number of drinks consumed [ Time Frame: Lab Session 1 (Day 1); Lab Session 2 (5-8 days after Lab Session 1). ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Connecticut Mental Health Center (SAC and SATU)New HavenConnecticut06511
Thomas B Liss, BS
[email protected]
203 974 5767
Nicolas Franco, BA
[email protected]
203 974-5759
Yale New Haven HospitalNew HavenConnecticut06512
Suchitra Krishnan-Sarin, PhD
[email protected]
(203) 974-7595
Thomas Liss
[email protected]
(203)974-7555
Suchitra Krishnan-Sarin, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By research site
Connecticut Mental Health Center (SAC and SATU)· New Haven, CTYale New Haven Hospital· New Haven, CT

Related Studies